Conduit Pharmaceuticals Inc. financial data

Symbol
CDT, CDTTW on Nasdaq
Industry
Pharmaceutical Preparations
Location
4995 Murphy Canyon Road, Suite 300, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Murphy Canyon Acquisition Corp. (to 9/21/2023)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 186 % +395%
Debt-to-equity -372 % -467%
Return On Equity 225 % +193%
Return On Assets -82.9 % -258%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96M shares
Common Stock, Shares, Outstanding 74M shares
Entity Public Float 23.2M USD -82.5%
Common Stock, Value, Issued 7K USD
Weighted Average Number of Shares Outstanding, Basic 73.9M shares +14.3%
Weighted Average Number of Shares Outstanding, Diluted 73.9M shares +12.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 25K USD
General and Administrative Expense 8.28M USD +53.8%
Operating Income (Loss) -8.53M USD -56.5%
Nonoperating Income (Expense) 2.84M USD -184%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.14M USD -49.1%
Income Tax Expense (Benefit) 213K USD +616%
Net Income (Loss) Attributable to Parent -5.69M USD +31.4%
Earnings Per Share, Basic -0.07 USD/shares -133%
Earnings Per Share, Diluted -0.15 USD/shares -133%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 219K USD
Other Assets, Current 51K USD
Assets, Current 1.6M USD +78.9%
Property, Plant and Equipment, Net 50K USD
Operating Lease, Right-of-Use Asset 319K USD
Intangible Assets, Net (Excluding Goodwill) 5K USD
Assets 3.31M USD +267%
Accounts Payable, Current 1.06M USD
Employee-related Liabilities, Current 40K USD -88.2%
Accrued Liabilities, Current 24.5K USD -82.3%
Liabilities, Current 2.86M USD +40.9%
Operating Lease, Liability, Noncurrent 141K USD
Liabilities 8.77M USD +31.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 387K USD
Retained Earnings (Accumulated Deficit) -20.2M USD -39.1%
Stockholders' Equity Attributable to Parent -5.46M USD +62.4%
Liabilities and Equity 3.31M USD +267%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.36M USD -19.6%
Net Cash Provided by (Used in) Financing Activities 2.22M USD -98.4%
Net Cash Provided by (Used in) Investing Activities -243K USD +99.8%
Common Stock, Shares Authorized 250M shares
Common Stock, Shares, Issued 74M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.38M USD -29900%
Interest Paid, Excluding Capitalized Interest, Operating Activities 80K USD
Deferred Tax Assets, Valuation Allowance 1.45M USD +585%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.43 pure
Deferred Tax Assets, Gross 1.45M USD +585%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.33M USD -116%
Operating Lease, Liability, Current 144K USD
Deferred Tax Assets, Operating Loss Carryforwards 813K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 14.4M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 10K USD
Interest Expense 100K USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%